The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir Is Associated With Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 31 (1) , 45-49
- https://doi.org/10.1097/00126334-200209010-00006
Abstract
Mycophenolic acid (MPA) enhances the in vitro activity of abacavir (ABC) and other nucleoside analog reverse transcriptase inhibitors (NRTIs) against sensitive and NRTI-resistant HIV-1. This may occur via depletion of intracellular deoxyguanosine triphosphate (dGTP). Mycophenolate mofetil (MMF) 500 mg twice daily was added as a single agent to the antiretroviral regimens of five patients failing maximal available therapy. Therapy included ABC, and in most cases didanosine (DDI) and tenofovir (TDF). At entry, mean plasma HIV-1 RNA (VL) was 5.02 log10 copies/mL (median 4.78, range 4.71-5.63) and mean CD4 count was 106/μL (median 117, range 11-174). MMF was well tolerated. CD4 cell counts did not change significantly from baseline for up to 60 weeks of follow-up. Three of five subjects had VL declines of >0.5 log10 copies/mL immediately after adding MMF; a fourth subject had a sustained decline of >0.5 log10 copies/mL after week 8. Declines of >0.5 log10 copies/mL were lost in two patients at 6 and 8 weeks, and persisted in two patients at 36 and 60 weeks of follow-up, respectively. An increase in the ratio of carbovir triphosphate (CBV-TP), the active antiviral metabolite of ABC, to dGTP was documented in 3 of 4 subjects in temporal association with decreased VL. Trough plasma MPA levels ranged from 0.26-1.67 μg/mL; peak levels 90 minutes after dosing from 1.20-7.77 μg/mL. AUC of MPA appeared little changed when measured over 28 weeks of therapy. Declines in VL were observed in association with measurable changes in the CBV-TP/dGTP ratio in some patients, whereas MPA AUC was below the 30-60 μg*hr/mL range targeted in organ transplantation. The possibility that MMF may enhance the effect of selected NRTIs and be tolerated in late stage HIV disease deserves careful randomized study.Keywords
This publication has 15 references indexed in Scilit:
- Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV ActivityJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2002
- A Pilot Study of the Use of Mycophenolate Mofetil as a Component of Therapy for Multidrug-Resistant HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivoNature Medicine, 2000
- Abacavir in Combination With the Inosine Monophosphate Dehydrogenase (IMPDH)–Inhibitor Mycophenolic Acid Is Active Against Multidrug-Resistant HIV-1JAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*Clinical Pharmacology & Therapeutics, 1998
- Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acidClinical Biochemistry, 1998
- Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89Antimicrobial Agents and Chemotherapy, 1997
- Polymerase Substrate Depletion: A Novel Strategy for Inhibiting the Replication of the Human Immunodeficiency VirusVirology, 1995
- Mechanisms of Action of Mycophenolic AcidAnnals of the New York Academy of Sciences, 1993